⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Aspirin on CTCs of Advanced Breast and Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Aspirin on CTCs of Advanced Breast and Colorectal Cancer

Official Title:

Study ID: NCT02602938

Interventions

Aspirin

Study Description

Brief Summary: The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.

Detailed Description: BACKGROUND: * Invasion and metastasis are the main reason of death in metastatic cancer, and abundant evidence find circulating tumor cells(CTCs) take the core position in breast and colorectal cancer metastasis. * Platelets play multiple role to facilitate the epithelial to mesenchymal transition of tumor cells and protect CTCs to survival in the circulation, which enrolled in the whole process of metastasis. * Several clinical trials and observational study have validate the primary and secondary prevention effect of aspirin to both breast and colorectal cancer. OBJECTIVES: * Determine the effect of aspirin on CTC number of metastatic breast and colorectal cancer; * Determine the effect of aspirin on CTC subtype (epithelial/mesenchymal/mixed type) of metastatic breast and colorectal cancer. ELIGIBILITY: * Adults age from 18-75 years old. * Patients were diagnosed for metastatic breast or colorectal cancer by pathology. * Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted. Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted. * No disease of hemorrhagic tendency or history of non-steroid drug allergy. * CTCs≥5 / 7.5ml blood STUDY DESIGN: * Aspirin will be administered orally once a day in 28-day cycles. * The CTC was evaluated every 28 days for 2 months.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: